Cystic Fibrosis Research and Translation Centers
Alabama
UAB
+
-
University of Alabama at Birmingham Cystic Fibrosis Research and Translation Core Center
Director: Steven M. Rowe, MD, MSPH
UAB has positioned itself as an emerging leader in CF patient oriented research, expanding clinical and translation research. An essential goal of the UAB Cystic Fibrosis Research and Translation Core Center is to propel investigators at UAB and collaborating sites towards improved understanding of the most basic underpinnings of cystic fibrosis pathogenesis, and the ways this information can be aggressively applied to experimental therapeutics.
UCSF
UCSF
+
-
University of California San Francisco Novel Small-Molecule Therapies for Cystic Fibrosis
Director: Alan S. Verkman, MD, PhD
The focus of the UCSF Core Center remains the discovery and evaluation of novel small-molecule therapies for CF. The mission of the Novel Small-Molecule Therapies for Cystic Fibrosis Center is to progress the five years of work establishing a unique academic drug discovery program in the laboratories of Dr. Verkman and collaborators to identify and characterize small-molecule modulators of CFTR activity.
Iowa
Iowa
+
-
University of Iowa Center for Gene Therapy of Cystic Fibrosis
Director: John F. Engelhardt, PhD
The Center for Gene Therapy of Cystic Fibrosis (CF) seeks to improve the quality of life for CF patients by both enhancing the field's understanding of CF pathogenesis and developing molecular therapies. The Center acts as a conduit that brings new talented investigators into the field of CF research and enhances the research infrastructure needed for collaborative discoveries and the development of novel therapies.
UNC
UNC
+
-
University of North Carolina Cystic Fibrosis Research and Translation Core Center
Director: Richard C. Boucher, MD
The UNC CF Research and Translation Core has set as its long-term goal the systemic "cure" of the cystic fibrosis (CF) phenotype. UNC's CF research base is broad and encompasses groups with expertise in CFTR biogenesis/ion transport, gene therapy, epithelial cell biology, mucus/mucin biochemistry and biophysics, microbiology/immunology, pulmonary transplant, and clinical research.
Pennsylvania
UPenn
+
-
University of Pennsylvania Molecular Therapy for Cystic Fibrosis
Director: James M. Wilson, MD, PhD
The Molecular Therapy for Cystic Fibrosis (CF) at UPenn has been transformed into a consortium consisting of four renowned institutions with a long-standing history in basic and translational CF research: UPenn, University of Massachusetts Medical School, Johns Hopkins University and the United Kingdom CF Gene Therapy Consortium. Each of these centers brings with it experience in vector development, animal models, airway gene delivery, design and support of IND-enabling studies and progression into clinical trials to support the mission of our Center which is innovative translational research for CF therapies.
Pittsburgh
Pitt
+
-
University of Pittsburgh Basic and Translational Studies of Cystic Fibrosis
Director: Raymond A. Frizzell, PhD
The central goal of the Cystic Fibrosis Research Center (CFRC) at the University of Pittsburgh is to understand the basic mechanisms of CF disease and translate that understanding to provide improved treatments that will enhance the quality of life and lifespan of CF patients. Our strategy is to implement this goal using the Center's strengths in the Molecular and Cell Biology of CFTR, CFTR mutants and other transporters, Infection and Inflammation, with the overall theme of translating our preclinical science discoveries into clinical investigations.
Washington
Washington
+
-
University of Washington Cystic Fibrosis Research and Translation Center
Director: Bonnie Ramsey, MD, Co-Director: Peter Greenberg, MD
The UW CFRTC focuses its research on developing new and improved treatments for patients with Cystic Fibrosis. The Center has a long history of strong partnerships between laboratory and clinically based scientists working together to take observations from the laboratory and transforming these findings into better drugs to treat the nutritional, metabolic and lung aspects of this fatal genetic disease.